Evidence map›Paper›PMID 33905484›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Forecasting Trachoma Control and Identifying Transmission-Hotspots.

Seth Blumberg, Joaquin M Prada, Christine Tedijanto, Michael S Deiner, William W Godwin, Paul M Emerson, Pamela J Hooper, Anna Borlase, T Deirdre Hollingsworth, Catherine E Oldenburg and 3 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. What Can Modeling Tell Us About Sustainable End Points for Neglected Tropical Diseases?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Seth BlumbergFrancis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.
Joaquin M PradaFaculty of Health and Medical Sciences, School of Veterinary Medicine, University of Surrey, Guildford, UK.
Christine TedijantoFrancis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.
Michael S DeinerFrancis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.
William W GodwinFrancis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.
Paul M EmersonInternational Trachoma Initiative, The Task Force for Global Health, Decatur, Georgia, USA.
Pamela J HooperInternational Trachoma Initiative, The Task Force for Global Health, Decatur, Georgia, USA.
Anna BorlaseNuffield Department of Medicine, Medical Sciences Division, University of Oxford, Oxford, UK.
T Deirdre HollingsworthNuffield Department of Medicine, Medical Sciences Division, University of Oxford, Oxford, UK.
Catherine E OldenburgFrancis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.
Travis C PorcoFrancis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.
Benjamin F ArnoldFrancis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.
Thomas M LietmanFrancis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.

Funding

UCSF-Proctor Clinician Vision Scholars K12 ProgramK12EY031372 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THOMAS M LIETMAN, Yvonne Ou · 2020 to 2026
$3.9M
Forecasting Trachoma Control - Diversity SupplementR01EY025350 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THOMAS M LIETMAN, Travis Christian Porco · 2016 to 2026
$3.3M
NEI NIH HHS K12 EY031372NEI NIH HHS R01 EY025350
6 · The paper itself

Abstract

backgroundTremendous progress towards elimination of trachoma as a public health problem has been made. However, there are areas where the clinical indicator of disease, trachomatous inflammation-follicular (TF), remains prevalent. We quantify the progress that has been made, and forecast how TF prevalence will evolve with current interventions. We also determine the probability that a district is a transmission-hotspot based on its TF prevalence (ie, reproduction number greater than one).

methodsData on trachoma prevalence come from the GET2020 global repository organized by the World Health Organization and the International Trachoma Initiative. Forecasts of TF prevalence and the percent of districts with local control is achieved by regressing the coefficients of a fitted exponential distribution for the year-by-year distribution of TF prevalence. The probability of a district being a transmission-hotspot is extrapolated from the residuals of the regression.

resultsForecasts suggest that with current interventions, 96.5% of surveyed districts will have TF prevalence among children aged 1-9 years <5% by 2030 (95% CI: 86.6%-100.0%). Districts with TF prevalence < 20% appear unlikely to be transmission-hotspots. However, a district having TF prevalence of over 28% in 2016-2019 corresponds to at least 50% probability of being a transmission-hotspot.

conclusionsSustainable control of trachoma appears achievable. However there are transmission-hotspots that are not responding to annual mass drug administration of azithromycin and require enhanced treatment in order to reach local control.

Indexed as

TrachomaAnti-Bacterial AgentsAzithromycinChildCross-Sectional StudiesHumansInfantMass Drug AdministrationPrevalenceAnti-Bacterial AgentsAzithromycincontroleliminationforecastsurveillancetrachoma

Identifiers

PMID33905484
PMCPMC8201580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.